Fulltext

Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies

Hassoun-Kheir N 1 , Guedes M 2 , Arieti F 3 , Pezzani MD 3 , Gladstone BP 4 , Robotham JV 5 Show all authors , Pouwels KB 6 , Kingston R 5 , Carmeli Y 7 , Cassini A 8 , Cecchini M 9 , Drobniewski F 10 , Frost I 11 , Geurtsen J 12 , Kronenberg A 13 , Htay MNN 14 , Paul M 15 , Rocha-Pereira N 16 , Rodríguez-Baño J 17 , Scudeller L 18 , Stewardson AJ 19 , Tacconelli E 3 , Harbarth S 1 , Vella V 20 , de Kraker ME 1

Affiliations 

  • 1 Infection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Geneva, Switzerland
  • 2 Instituto de Biomedicina de Sevilla (IBiS), Infectious Diseases and Microbiology Division, Hospital Universitario Virgen Macarena, Department of Medicine, University of Sevilla/CSIC, Sevilla, Spain
  • 3 Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
  • 4 DZIF-Clinical Research Unit, Infectious Diseases, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany
  • 5 HCAI, Fungal, AMR, AMU & Sepsis Division, UK Health Security Agency, London, United Kingdom
  • 6 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • 7 National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • 8 Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland and Public Health Department, Canton of Vaud, Lausanne, Switzerland
  • 9 Head of Public Health, Health Division, OECD (Organisation for Economic Co-operation and Development), Paris, France
  • 10 Department of Infectious Disease, Imperial College London, London, United Kingdom
  • 11 AstraZeneca, Eastbrook House, Cambridge, United Kingdom
  • 12 Bacterial Vaccines Research & Early Development, Janssen Vaccines & Prevention B.V., Leiden, the Netherlands
  • 13 Swiss Centre for Antibiotic Resistance, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
  • 14 Department of Community Medicine, Faculty of Medicine, Manipal University College Malaysia, Melaka, Malaysia
  • 15 Infectious Diseases Institute, Rambam Health Care Campus; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
  • 16 Department of Medicine, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
  • 17 CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain
  • 18 Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
  • 19 Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Victoria, Australia
  • 20 GSK, Siena, Italy
Euro Surveill, 2024 Nov;29(47).
PMID: 39574390 DOI: 10.2807/1560-7917.ES.2024.29.47.2400212

Abstract

To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant Klebsiella pneumoniae and Escherichia coli, for bloodstream and urinary tract infections, respectively, and meticillin-resistant Staphylococcus aureus for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications